<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103750</url>
  </required_header>
  <id_info>
    <org_study_id>1612018712</org_study_id>
    <secondary_id>M# 25288</secondary_id>
    <nct_id>NCT03103750</nct_id>
  </id_info>
  <brief_title>Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD</brief_title>
  <official_title>Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Study of Stimulant-induced Dopamine Release Using [11C]-Raclopride PET in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brain &amp; Behavior Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim 1: As part of a within-subject, two-days, study design, to determine whether
      acute calcitriol (vs. placebo) pre-treatment is associated with greater amphetamine
      (Amp)-induced dopamine (DA) release in the caudate, putamen, ventral striatum (VST), and
      substantia nigra / ventral tegmental area (SN/VTA) of healthy human subjects.

      Specific Aim 2: To determine whether acute calcitriol (vs. placebo) pre-treatment is
      associated with better performance on a test of attention (e.g., the continuous Performance
      Task or CPT-AX), after treatment with amphetamine. Hypothesis: Investigators hypothesize that
      Subjects pre-treated with calcitriol will have faster reaction times/higher accuracy on the
      CPT-AX vs. subjects pre-treated with placebo, after treatment with amphetamine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increases in the rates of childhood ADHD over the past two decades have lead to speculation
      that calcitriol deficiency (e.g., secondary to the increased use of sunscreen and/or
      increases in sedentary, indoor lifestyles in children) plays a causal/contributory role in
      the etiology of ADHD. To date, evidence of a direct link is lacking. One study showed higher
      maternal circulating Vitamin D levels in pregnancy are associated with lower risk of
      developing ADHD-like symptoms in childhood. On the other hand, another study did not
      replicate the above association, and a prospective study using umbilical cord samples stored
      at the time of birth reported no difference in serum vitamin D levels between ADHD group
      versus healthy controls. In terms of clinical trials, one randomized double blind study among
      adults with ADHD reported a beneficial effect of the intervention, measured with the Conners
      Adult ADHR rating scale, in comparison with placebo, but the intervention included the
      combination of vitamin D and several other micronutrients. An analysis of moderators of a
      positive response to ADHD behaviors did not reveal a significant predictive effect of vitamin
      D.

      However, recent studies provide intriguing indirect evidence of an inverse relationship
      between solar intensity (SI) and/or altitude (a proxy for greater sun/UV light exposure) and
      regional rates of ADHD. One study examined three large datasets across 49 U.S. states for
      2003 and 2007, and across 9 non-U.S. countries. This study examined the prevalence of ADHD
      and Solar Intensity (SI) maps. They found an inverse association between solar intensity and
      prevalence of ADHD. Another study examined two national survey datasets. They found an
      inverse relationship between altitude and prevalence of ADHD. Investigators hypothesize, as
      suggested by Huber, that a common denominator on the above studies is the increased vitamin D
      levels in those exposed to a higher solar intensity, which is known to increase with
      altitude.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a within-subject, two-day four-scan, randomized, double-blind, placebo-controlled study design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>non-displaceable tracer binding potentials</measure>
    <time_frame>day 1</time_frame>
    <description>non-displaceable tracer binding potentials (BPND = VT - VREF / VREF), which are linearly proportional to the density of available D2/3 Rs, computed using a simplified reference tissue model (SRTM) utilizing the cerebellum as a reference region.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>non-displaceable tracer binding potentials</measure>
    <time_frame>day 7</time_frame>
    <description>non-displaceable tracer binding potentials (BPND = VT - VREF / VREF), which are linearly proportional to the density of available D2/3 Rs, computed using a simplified reference tissue model (SRTM) utilizing the cerebellum as a reference region.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>continuous Performance Task (CPT-AX)</measure>
    <time_frame>day 1</time_frame>
    <description>In this computer based test the subjects are shown a random sequence of different letters and are instructed to press a button as quickly and accurately as possible (with their preferred hand) upon detection of an X after an A, and to withhold their response to any other sequence of letters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>continuous Performance Task (CPT-AX)</measure>
    <time_frame>day 7</time_frame>
    <description>In this computer based test the subjects are shown a random sequence of different letters and are instructed to press a button as quickly and accurately as possible (with their preferred hand) upon detection of an X after an A, and to withhold their response to any other sequence of letters.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Calcitriol then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by Raclopride injection &amp; PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second Racloporide injection and PET scan #2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by Raclopride injection &amp; PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second Racloporide injection and PET scan #2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis</description>
    <arm_group_label>Calcitriol then placebo</arm_group_label>
    <arm_group_label>Placebo then Calcitriol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raclopride</intervention_name>
    <description>Used as a tracer for in vivo imaging.</description>
    <arm_group_label>Calcitriol then placebo</arm_group_label>
    <arm_group_label>Placebo then Calcitriol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcitriol</intervention_name>
    <description>three 0.5 mcg capsules</description>
    <arm_group_label>Calcitriol then placebo</arm_group_label>
    <arm_group_label>Placebo then Calcitriol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>three 0.5 mcg capsules</description>
    <arm_group_label>Calcitriol then placebo</arm_group_label>
    <arm_group_label>Placebo then Calcitriol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high-resolution research tomography</intervention_name>
    <description>A functional imaging technique that is used to observe metabolic processes in the body.</description>
    <arm_group_label>Calcitriol then placebo</arm_group_label>
    <arm_group_label>Placebo then Calcitriol</arm_group_label>
    <other_name>PET scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextro Amphetamine</intervention_name>
    <description>Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg</description>
    <arm_group_label>Calcitriol then placebo</arm_group_label>
    <arm_group_label>Placebo then Calcitriol</arm_group_label>
    <other_name>Dexedrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50 years

          -  Voluntary, written, informed consent

          -  Physically healthy by medical history, physical, neurological, ECG, and laboratory
             examinations

          -  For females, non-lactating, with a negative serum or urine pregnancy test

          -  Lab results without clinically relevant findings (e.g. renal function, electrolytes,
             and vitamin D levels)

          -  English speaking

        Exclusion Criteria:

          -  Medical contraindication to Dexedrine administration (e.g., history of cardiac
             problems, seizures, glaucoma, hypertension, hyperthyroidism, etc.)

          -  Medical contraindication to calcitriol administration (e.g., history of
             hypersensitivity to calcitriol or any component of the formulation, hypercalcemia or
             vitamin D toxicity)

          -  History of substance dependence (e.g., alcohol, opiates, sedative hypnotics), except
             for nicotine

          -  A primary major DSM-V psychiatric disorder (e.g., schizophrenia, bipolar disorder,
             major depression, etc.) as determined by the Structured Clinical Interview for DSM-V
             (SCID)

          -  A history of significant medical (e.g., cardiovascular, diabetic/metabolic) or
             neurological (e.g., cerebrovascular accidents, seizure, traumatic brain injury)
             illness

          -  Positive answers on the cardiac history questionnaire that may place the subject at
             higher risk, as determined by an internal medicine specialist or cardiologist's review
             of both the questionnaire responses and screening ECG

          -  Current use of psychotropic and/or potentially psychoactive prescription medications

          -  For females, laboratory (Î²-HCG) or physical evidence of pregnancy/lactation 9)
             MRI-incompatible implants and other contraindications for MRI (i.e., aneurysm clip,
             metal fragments, internal electrical devices such as a cochlear implant, spinal cord
             stimulator or pacemaker)

          -  History of claustrophobia or feeling of inability to lie still on his/her back for the
             PET or MRI scans

          -  History of any bleeding disorder or current anticoagulant therapy

          -  Donation or loss of 550 mL of blood or more (including plasmapheresis) or receipt of a
             transfusion of any blood product within 8 weeks prior to the first test day.

          -  Use of any prescription medications and/or over-the-counter medications, vitamins
             and/or herbal supplements which could have a negative clinical interaction with
             calcitriol/Dexedrine or which could confound scientific results of the study, within 2
             weeks prior to each test day (e.g., thiazide diuretics, Mg based antiacids, digoxin,
             etc,.).

          -  Serum levels of 25(OH)D3 below 20 ng/ml.

          -  Obesity i.e. BMI over 30 (more prone to lower vitamin D levels)

          -  Subjects with history of prior radiation exposure for research purposes within the
             past year such that participation in this study would place them over Radioactive Drug
             Research Committee (RDRC) limits for annual radiation exposure. This guideline is an
             effective dose of 5 rem received per year.

          -  Subjects with current, past or anticipated exposure to radiation in the work place

          -  History of kidney stones within the past 5 years

          -  Any degree of renal failure

          -  History of parathyroid disorder (hyper or hypoparathyroidism)

          -  History of osteoporosis or any pathologic fractures

          -  Vitamin D supplementation in any form in the past 3 months

          -  Known hypersensitivity to Dexedrine, [11C] Raclopride, or calcitriol

          -  Malabsorption syndromes (i.e. Celiac sprue)

          -  Serum corrected calcium &gt; 10.5 mg/dl or phosphate &gt; 4.2 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo A Angarita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Costeines, MSW</last_name>
    <phone>203-974-7559</phone>
    <email>Jessica.costeines@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Costeines, MSW</last_name>
      <phone>203-974-7559</phone>
      <email>jessica.costeines@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Robert T Malison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
    <mesh_term>Central Nervous System Stimulants</mesh_term>
    <mesh_term>Raclopride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

